Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Quality of Life of Patients Treated With Opium Tincture or Methadone: A Randomized Controlled Trial Publisher Pubmed



Kim JJ1 ; Nikoo M1 ; Nikoo N2 ; Javidanbardan S2 ; Kazemi A1 ; Choi F1 ; Gholami A3 ; Lafooraki NY4 ; Vogel M5 ; Rezazadehazar P6 ; Meyer M7 ; Cabanis M8 ; Jang K1 ; Aknondzadeh S9 Show All Authors
Authors
  1. Kim JJ1
  2. Nikoo M1
  3. Nikoo N2
  4. Javidanbardan S2
  5. Kazemi A1
  6. Choi F1
  7. Gholami A3
  8. Lafooraki NY4
  9. Vogel M5
  10. Rezazadehazar P6
  11. Meyer M7
  12. Cabanis M8
  13. Jang K1
  14. Aknondzadeh S9
  15. Krausz M1
Show Affiliations
Authors Affiliations
  1. 1. Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, V6T 2A1, Canada
  2. 2. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
  3. 3. Kian Methadone Maintenance Treatment Clinic, Mazandaran, Sari, Iran
  4. 4. Islamic Azad University, Science and Research Branch, Mazandaran, Iran
  5. 5. Division of Substance Use Disorders, University of Basel Psychiatric Clinics, Basel, Switzerland
  6. 6. Complex Pain and Addiction Services, Vancouver General Hospital & Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
  7. 7. University Psychiatric Clinics Basel, University of Basel, Basel, Switzerland
  8. 8. Center for Mental Health, Clinic for Addiction Medicine and Addictive Behavior, Klinikum Stuttgart, Stuttgart, 70374, Germany
  9. 9. Psychiatric Research Center, Roozbeh Hospital, Department of Psychiatry, Faculty of Medicine, Tehran University of Medical Sciences, Iran

Source: Drug and Alcohol Dependence Published:2023


Abstract

Objective: Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the QoL of participants with opioid use disorder receiving OAT using OT or methadone and identify the factors associated with their QoL during treatment. Methods: The opium trial was a multicenter non-inferiority randomized clinical trial in four private OAT outpatient clinics in Iran. The study assigned patients to either OT (10 mg/ml) or methadone sirup (5 mg/ml) for a follow-up of 85 days. QoL was assessed using the brief version of the World Health Organization Quality of Life instrument (WHOQOL- BREF). Results: A total of 83 participants, 35 (42.2%) in the OT arm and 48 (57.8%) in the methadone arm, completed the WHOQOL-BREF in full and were included in the primary analysis. The mean score of patients’ QoL showed improvement compared to baseline, but differences were not statistically significant between OT and methadone arms (p = 0.786). Improvements were mainly observed within the first 30 days of receiving treatment. Being married and lower psychological distress were associated with an improved QoL. Within the social relationships domain, male gender showed significantly higher QoL compared to females. Conclusion: OT shows promise as an OAT medication, comparable to methadone in improving patients’ QoL. There is a need to incorporate psychosocial interventions to further sustain and improve the QoL in this population. Identifying other social determinants of health which affect QoL and the cultural adaptation of assessments for individuals from various ethnocultural backgrounds are critical areas of inquiry. © 2023 Elsevier B.V.